Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ROMIPLOSTIM Cause Therapy non-responder? 224 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 224 reports of Therapy non-responder have been filed in association with ROMIPLOSTIM (Nplate). This represents 3.0% of all adverse event reports for ROMIPLOSTIM.

224
Reports of Therapy non-responder with ROMIPLOSTIM
3.0%
of all ROMIPLOSTIM reports
24
Deaths
50
Hospitalizations

How Dangerous Is Therapy non-responder From ROMIPLOSTIM?

Of the 224 reports, 24 (10.7%) resulted in death, 50 (22.3%) required hospitalization, and 6 (2.7%) were considered life-threatening.

Is Therapy non-responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ROMIPLOSTIM. However, 224 reports have been filed with the FAERS database.

What Other Side Effects Does ROMIPLOSTIM Cause?

Off label use (1,027) Platelet count decreased (892) Platelet count abnormal (703) Drug ineffective (513) Thrombocytopenia (369) Headache (359) Death (356) Product storage error (344) Fatigue (251) Circumstance or information capable of leading to medication error (238)

What Other Drugs Cause Therapy non-responder?

ETANERCEPT (3,472) APREMILAST (3,360) METHOTREXATE (2,965) RITUXIMAB (2,731) ADALIMUMAB (2,595) PREDNISONE (2,563) TREPROSTINIL (2,289) INFLIXIMAB (2,122) TOCILIZUMAB (1,775) HYDROXYCHLOROQUINE (1,699)

Which ROMIPLOSTIM Alternatives Have Lower Therapy non-responder Risk?

ROMIPLOSTIM vs ROMOSOZUMAB ROMIPLOSTIM vs ROMOSOZUMAB-AQQG ROMIPLOSTIM vs ROPEGINTERFERON ALFA-2B-NJFT ROMIPLOSTIM vs ROPINIROLE ROMIPLOSTIM vs ROPIVACAINE

Related Pages

ROMIPLOSTIM Full Profile All Therapy non-responder Reports All Drugs Causing Therapy non-responder ROMIPLOSTIM Demographics